Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Boardroom Talk: Summit Therapeutics' long road to drug approval

    Boardroom Talk: Summit Therapeutics' long road to drug approval

    FromInvestors' Chronicle

    Start listeningView podcast show

    Boardroom Talk: Summit Therapeutics' long road to drug approval

    FromInvestors' Chronicle

    ratings:
    Length:
    14 minutes
    Released:
    Mar 20, 2017
    Format:
    Podcast episode

    Description

    Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates. Hosted on Acast. See acast.com/privacy for more information.
    Released:
    Mar 20, 2017
    Format:
    Podcast episode

    Titles in the series (100)

    Concerned with QE's effects on equity valuations? Looking for ideas for your Isa? Or just plain confused by the stock market? Each week, the Investors Chronicle picks apart the latest news for companies, markets and funds in our regular magazine podcasts. Subscribe for these, along with CEO interviews, company-specific shows and special in-depth discussions on big market themes. Hosted on Acast. See acast.com/privacy for more information.